Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on January 24, 2023, regarding a corporate action approved by stockholders on January 4, 2023. The report details the implementation of a reverse stock split of the Company's common stock.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary quantitative data relates to capital structure adjustments:
- Pre-Split Outstanding Shares: Approximately 13.7 million shares.
- Post-Split Outstanding Shares: Approximately 1.1 million shares.
- Reverse Split Ratio: 1-for-12.
- Fractional Share Payment Rate: $6.51 per fractional share (based on the average closing price over ten trading days ending January 24, 2023).
Material Changes
The material change reported is the amendment to the Company's Amended and Restated Certificate of Incorporation to effect a 1-for-12 reverse stock split. Key changes include:
- Effective Date: The split became effective at 12:01 a.m. Eastern Time on January 26, 2023.
- Trading Resumption: Common stock began trading on The Nasdaq Capital Market on a post-split basis on January 26, 2023.
- Authorized Shares: The number of authorized shares was not reduced, increasing the number of shares available for issuance relative to issued and outstanding shares.
- Equity Awards: Proportionate adjustments were made to the per-share exercise price and number of shares issuable under outstanding equity awards and warrants.
- Identifiers: The trading symbol remains "PHIO," but the CUSIP number changed to 71880W402.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, forward-looking outlook, or management commentary regarding future business performance. The document focuses on the mechanics of the stock split. Notable operational details include:
- Fractional Shares: No fractional shares will be issued; holders entitled to fractions will receive cash payments.
- Share Registration: Post-split shares will be issued via Computershare's paperless Direct Registration System (DRS).
- Par Value and Rights: The par value ($0.0001) and voting rights of the common stock remain unchanged.
Investor Verification Checklist
- Verify the effective date of the reverse stock split (January 26, 2023) and confirm trading status on The Nasdaq Capital Market.
- Confirm the new CUSIP number (71880W402) for post-split shares.
- Check broker instructions regarding the exchange of pre-split shares and the receipt of cash for fractional shares at the $6.51 rate.
- Review the impact of the 1-for-12 ratio on existing equity awards, warrants, and employee stock purchase plans.
- Monitor the increase in authorized but unissued shares available for future capital raises.